Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa
Highlights:
Trial meets its Primary Endpoint with 39% ORR (95%CI 22%-58%) in patients with advanced PEComa – a rare sarcoma with no currently approved therapy
First prospective clinical study in advanced ... Read More
admin
03
Jun2019
Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa
June, 3 2019, Aadi Bioscience, Inc. (Aadi), Aadi Bioscience, Inc (Aadi), a privately held clinical stage biopharmaceutical company, today released preliminary data on the ongoing nab-sirolimus (ABI-009) registration trial (AMPECT) for Advanced ... Read More
June 3, 2019admin
07
Mar2019
March, 7 2019, Aadi Bioscience, Inc. (Aadi), For the first time in his life, Shanahan “Shanny” Dameral, 19, has a girlfriend. Soon, he’ll be graduating with a high school diploma and looking for his first job on the Kitsap Peninsula.
What seems routine for many is a big deal for Dameral and ... Read More
March 7, 2019admin
03
Jan2019
January, 3 2019, Aadi Bioscience, Inc. (Aadi), a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced that its drug ABI-009 (sirolimus albumin-bound nanoparticles for injectable suspension) has received Breakthrough Therapy Designation status from the FDA for the indication of Advanced (metastatic or locally advanced) Malignant ... Read More
January 3, 2019admin
06
Oct2017
October, 6 2017, The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial
research grants totaling more than $22 million over the next four years to boost the development of
products for patients with rare diseases. These new grants were awarded to principal investigators
from academia and ... Read More
October 6, 2017admin
08
May2017
Aadi Bioscience, Inc. (Aadi), a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced the completion of a $23 Million Series A round. The financing was led by Hermed Capital with participation from Celgene Corporation, Vivo Capital, Decheng Capital, the Helsinn Investment Fund and Star ... Read More
May 8, 2017admin
02
Nov2015
Study to be conducted at major cancer centers across the US
PACIFIC PALISADES, Calif. (Nov 2, 2015) -- AADi Bioscience, LLC, a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced the initiation of its registration trial for advanced Perivascular Epithelioid Cell tumors (PEComa) with ABI-009, ... Read More
November 2, 2015admin
21
May2014
By Michael Fitzhugh, Staff Writer Aadi LLC.
A small new biotech company led by Abraxane (nab-paclitaxel) co-inventor Neil Desai, is in-licensing a once-shelved nanoparticle therapy from Celgene Corp. to develop it for oncology and cardiovascular indications. Celgene acquired the drug, ABI-009, in its 2010 acquisition of Abraxis Bioscience Inc. and retains ... Read More
May 21, 2014admin
20
May2014
AADi Initiates NIH Funded Clinical Trial for Patients with Bladder Cancer PACIFIC PALISADES, Calif. (May 20, 2014) -- AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches, today announced the inlicensing of ABI-009 from Celgene Corporation (NASDAQ:CELG).
ABI-009 is the nanoparticle albumin-bound (nab®) version ... Read More
May 20, 2014admin